Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evogene (EVGN) Payables (2016 - 2025)

Historic Payables for Evogene (EVGN) over the last 14 years, with Q3 2025 value amounting to $457000.0.

  • Evogene's Payables fell 6185.31% to $457000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $457000.0, marking a year-over-year decrease of 6185.31%. This contributed to the annual value of $1.2 million for FY2024, which is 3120.45% down from last year.
  • Evogene's Payables amounted to $457000.0 in Q3 2025, which was down 6185.31% from $557000.0 recorded in Q2 2025.
  • Evogene's Payables' 5-year high stood at $1.8 million during Q3 2021, with a 5-year trough of $457000.0 in Q3 2025.
  • Moreover, its 5-year median value for Payables was $1.2 million (2023), whereas its average is $1.1 million.
  • As far as peak fluctuations go, Evogene's Payables soared by 16390.87% in 2021, and later plummeted by 6185.31% in 2025.
  • Evogene's Payables (Quarter) stood at $1.5 million in 2021, then decreased by 29.19% to $1.0 million in 2022, then surged by 72.3% to $1.8 million in 2023, then crashed by 31.2% to $1.2 million in 2024, then plummeted by 62.79% to $457000.0 in 2025.
  • Its last three reported values are $457000.0 in Q3 2025, $557000.0 for Q2 2025, and $592000.0 during Q1 2025.